Bristol-Myers Squibb's (BMY) 'Disappointing' Opdivo Data in NSCLC has No Impact on Ratings - Moody's

Moody's Investors Service commented that Bristol-Myers Squibb's (NYSE: BMY) disappointing clinical trial result for Opdivo in first-line lung cancer is a setback because this indication represented a sizeable growth opportunity. There is no impact on Bristol's A2/Prime-1 ratings or stable rating outlook.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) Declares $0.63 Quarterly Dividend; 4.6% Yield
• H.C. Wainwright Starts Agomab Therapeutics (AGMB) at Buy
• Evercore ISI Starts Credo Tech (CRDO) at Outperform